⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Ocrelizumab for Pediatric Relapsing Multiple Sclerosis (P4-6.003)

Malak AlMojel Samar Farouk Ahmed Jasem Al–Hashel Raed Alroughani

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

To evaluate the effectiveness and safety of Ocrelizumab treatment for POMS, relapsing phenotype.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

AlMojel et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db64358767801e https://doi.org/10.1212/wnl.0000000000204784

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world Data on Ocrelizumab Treatment: Efficacy, Safety, and Tolerability Analysis in Patients with Relapsing Remitting and Primary Progressive Multiple Sclerosis in Southeastern Ontario (P2-6.014)2024
2Systematic review on Ocrevus for treatment of multiple sclerosis2024 · 1 citations
3Efficacy and Safety of Ocrelizumab Compared With Fingolimod in Pediatric-onset Relapsingremitting MS: Results of the Phase III OPERETTA Two Study (S40.005)Late-Phase Clinical Trial · 2026
410 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)2024 · 8 citations
5Ocrelizumab in early relapsing–remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohortCohort Study · 2026

More related papers

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease (S40.001)2026
Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension2023
Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis2025

More from Neurology

Role of APOE ɛ4 and ɛ2 With Longitudinal Cognitive Decline Among Those With Exceptional LongevityFri,
Associations of Antibodies Against Several Infections With Alzheimer Disease NeuropathologyFri,